NCT02570126 - A Safety and Immune Study of 2 Types of GlaxoSmithKline's Varicella Vaccines Given as a 2-doses Course to Healthy Children 12-23 Months of Age. | Biotech Hunter

Enrollment

1,236

Participants

Timeline

Start Date

November 13, 2015

Primary Completion Date

October 25, 2016

Study Completion Date

October 25, 2016

Conditions

Chicken-pox Illness (Varicella Virus Disease)Chickenpox

Interventions

BIOLOGICAL

Varilrix HSA-free

2 doses will be administered, one at Day 0 and the other at Day 42

BIOLOGICAL

Varilrix™

2 doses will be administered, one at Day 0 and the other at Day 42

Trial Locations (23)

10330

GSK Investigational Site, Bangkok

10617

GSK Investigational Site, Tallinn

13055

GSK Investigational Site, Berlin

24534

GSK Investigational Site, Neumünster

32756

GSK Investigational Site, Detmold

34246

GSK Investigational Site, Vellmar

42719

GSK Investigational Site, Solingen

50106

GSK Investigational Site, Tartu

63739

GSK Investigational Site, Aschaffenburg

67227

GSK Investigational Site, Frankenthal

70469

GSK Investigational Site, Stuttgart

70499

GSK Investigational Site, Stuttgart

77694

GSK Investigational Site, Kehl

83471

GSK Investigational Site, Schönau am Königssee

97070

GSK Investigational Site, Mérida

97941

GSK Investigational Site, Tauberbischofsheim

Unknown

GSK Investigational Site, Tallinn

04808

GSK Investigational Site, Wurzen

04530

GSK Investigational Site, Mexico City

BS2 8AE

GSK Investigational Site, Bristol

SW17 0RE

GSK Investigational Site, London

OX3 7LJ

GSK Investigational Site, Oxford

SO16 6YD

GSK Investigational Site, Southampton